Twin Path Ventures (BBI) investment portfolio

AMPLY Discovery is a UK biotechnology company that combines artificial‑intelligence engines with synthetic‑biology wet‑lab validation to discover novel therapeutics from the largely untapped non‑coding portion of the genome, targeting high‑impact diseases such as cancer and antimicrobial‑resistant infections. Its integrated platform links computational target identification, molecule design and experimental testing to deliver first‑in‑class drug candidates for pharmaceutical partners.

Composo provides software that automates the testing, evaluation and quality‑control of generative AI and large language model applications, delivering analysis, source citations and expert corrections. Its service is aimed at teams and enterprises building AI solutions across sectors such as healthcare, finance, legal and other enterprise domains.